Synovial Sarcoma Treatment MarketSize and Trends

Synovial Sarcoma Treatment Market Drivers

According to American Cancer Society estimates, the incidence of synovial sarcoma in the U.S. for 2018 is expected to be 13,040 patients out of which 7,370 in males and 5,670 in females. Extensive research & development in this field for the development of innovative therapies for the treatment of synovial sarcoma is expected to boost the global synovial sarcoma treatment market growth over the forecast period. For instance, organizations such as Accuronix Therapeutics, Advenchen Laboratories, LLC, Immune Design, Cue Biopharma, and others are working on research and development of novel immunotherapy candidates for the treatment of synovial sarcoma. Accuronix Therapeutics has ACXT-3102, a small molecule drug conjugate, in preclinical development for treatment of synovial sarcoma and other cancers. Advanchen Laboratories has AL3818 (anlotinib) in Phase 3 clinical trials for the treatment of synovial sarcoma (SS), and other indications. Moreover, Immune Design has an antigen-specific prime boost CMB305 in Phase 2 clinical trials for synovial sarcoma. Cue Biopharma is working on CUE-102, a potential treatment for melanoma, synovial sarcoma, prostate, and head and neck cancers.

Adaptimmune Therapeutics received T-Cell therapy breakthrough designation by the U.S. Food & Drug Administration (FDA) for its NY-ESO-1 T-cell therapy in 2016. Immunocore, a U.K. based biotechnology company is working on ImmTAC (Immune mobilizing monoclonal TCRs), which has potential applications in various cancers including synovial sarcoma. Furthermore, research on novel vaccines for the treatment of synovial sarcoma is also underway, which could increase the treatment options for synovial sarcoma. These factors are expected to boost growth of the synovial sarcoma treatment market over the forecast period.